Antibody-Based Inhibition of Uropathogenic E. coli Adhesion
The technology offers innovative antibody compositions that target the FimH adhesin of uropathogenic E. coli, preventing bacterial adhesion and biofilm formation.
Bikunin Biomimetic with Anti-Inflammatory and Antiviral Activity
The solution is a serine protease inhibitor, bikunin, that plays a role in controlling the early immune response to Influenza A virus.
Novel Nanoparticle Immunogens for Influenza Vaccines
This technology offers a new approach to influenza vaccines using computationally designed nanoparticle immunogens that elicit potent, neutralizing antibodies against influenza viruses.
Repurposing Combinations of Approved Drugs for Viral Outbreak Response and Readiness
The collection of technologies offers a simple yet powerful method for identifying combinations of previously FDA approved drugs with synergistic activity against viral infections. The technology is available for immediate use in preparation IND-enabling studies in high impact viral disease areas.
Secretion-Optimized Protein Nanoparticles for Eukaryotic Expression and Genetic Delivery
This technology offers innovative protein nanoparticles designed for efficient secretion in eukaryotic cells, enhancing genetic delivery and therapeutic applications.
Targeted Protein Degradation in Bacteria Contributes to Antibiotic Efficacy
The solution is a method to develop new antibiotic proteolysis targeting chimeras (PROTACs) that target proteins of interest for degradation in bacteria to counteract antibiotic resistance.
Treponema Pallidum-Specific Aptamers for Syphilis Diagnostics
The solution is the development of Treponema pallidum-specific aptamers to be used in accurate point-of-care diagnostic assays for syphilis.